MAM
HDFC MF boards the Jagriti Yatra for Bharat’s future
MUMBAI: The 18th edition of Jagriti Yatra, India’s iconic journey of enterprise and inspiration, set off from Mumbai on 7 November, powered this year by HDFC Mutual Fund through its investor education and awareness initiative.
The 15-day, 8,000-kilometre expedition brings together 500 spirited “Yatris” from across India and beyond, chosen from over 68,000 applicants. Their shared destination, an Atmanirbhar Bharat built through ideas, innovation and enterprise.
Speaking at the flag-off in Mumbai’s Bal Gandharva Rang Mandir, HDFC Asset Management Company MD and CEO Navneet Munot, connected India’s entrepreneurial pulse with the nation’s long-term vision of Viksit Bharat 2047. He said empowerment begins with awareness of one’s potential and financial choices. Through its education initiatives, HDFC Mutual Fund aims to help young Indians make informed investment decisions and take confident steps toward financial independence.
Jagriti Yatra founder and MP Shashank Mani reminded participants that the movement’s spirit lies in responsibility and resilience, while CEO Ashutosh Kumar called it a “living classroom” for self-reliance born from local innovation.
The evening featured a stirring keynote by Mann Deshi foundation founder Chetna Gala Sinha, who urged the Yatris to channel resilience into enterprise. Performances by ANKH Ensemble and Folk Masti added rhythm to reflection, celebrating India’s creative energy and unity in diversity.
Over the years, Jagriti Yatra has become one of the world’s largest entrepreneurial journeys on wheels, touching more than 8,000 participants. This year’s train, aptly dubbed the Jagriti Express, will travel across Ahmedabad, Kochi, Hubli and beyond, with mentors such as Ashwin Naik, Sameer K. Mody, and Vishal Dhale guiding the travellers.
As the train leaves Mumbai, it carries more than people, it carries purpose. Each Yatri, and each partner like HDFC Mutual Fund, is helping steer India toward a future powered by awareness, enterprise and self-belief.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
